M1002

Research use only, not for human use.

M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist that enhances the affinity of HIF-2alpha and ARNT for transcriptional activation.

M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors.

M1002 (10 μM; 24 h) enhances the expression of HIF-2 target genes with great efficacy.M1002 (5 μM; 24 h) treatment shows synergy with prolyl hydroxylase domain (PHD) inhibitors.RT-PCR Cell Line:786-O cells Concentration:10 μM Incubation Time:24 hoursResult:Showed clear agonistic effects on the expression of HIF-2 target genes in 786-O cells as compared with the control.RT-PCR Cell Line:Hep3B cells Concentration:5 μM Incubation Time:24 hours Result:Elevated the expression of EPO and NDRG1 by co-treatment of M1002 together with PHD inhibitors, compared with M1002 alone treatment.

——

——

Angiogenesis

HIF/HIF Prolyl-hydroxylase

HIF

——

——

823830-85-9

394.29

C15H8F6N2O2S

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (126.81 mM; Ultrasonic (<60°C); )DMF : 50 mg/mL (126.81 mM; Ultrasonic)

FC(F)(F)C1=CC(=CC(NC2=NS(=O)(=O)C3=CC=CC=C23)=C1)C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years